However, the clinical research on RET inhibitors in NSCLC is just beginning and a number of relevant questions remain to be addressed: what is the best RET inhibitor for patients with advanced NSCLC and what will be their impact on overall survival? This evidence concerns the gene RET and non-small cell lung carcinoma.